CXCL10 and neoplasm: To our knowledge, we are the first to report that blocking GBE1 promotes the production of CCL5 and CXCL10, which also recruits CD8+ T lymphocytes into the tumor microenvironment, and GBE1 might be a potential target for achieving tumor regression in lung adenocarcinoma (LUAD)14.